Oligodendroglioma - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Oligodendroglioma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Oligodendroglioma - Pipeline Review, H1 2015’, provides an overview of the Oligodendroglioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Oligodendroglioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Oligodendroglioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oligodendroglioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oligodendroglioma Overview 8
Therapeutics Development 9
Pipeline Products for Oligodendroglioma - Overview 9
Pipeline Products for Oligodendroglioma - Comparative Analysis 10
Oligodendroglioma - Therapeutics under Development by Companies 11
Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes 12
Oligodendroglioma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Oligodendroglioma - Products under Development by Companies 15
Oligodendroglioma - Products under Investigation by Universities/Institutes 16
Oligodendroglioma - Companies Involved in Therapeutics Development 17
Cavion LLC 17
Celgene Corporation 18
Celldex Therapeutics, Inc. 19
e-Therapeutics plc 20
Eli Lilly and Company 21
F. Hoffmann-La Roche Ltd. 22
Millennium Pharmaceuticals, Inc. 23
Novartis AG 24
Orbus Therapeutics, Inc. 25
Sanofi 26
Tocagen Inc. 27
Oligodendroglioma - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
alisertib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
bevacizumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CC-122 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Dendritic Cell Therapy for Gliomas - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dendritic Cell Therapy for Oncology - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DNX-2401 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eflornithine hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ETS-2101 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
galunisertib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
mibefradil dihydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
panobinostat - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
plerixafor - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
rindopepimut - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Stem Cell Therapy for Glioma - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Oligodendroglioma - Recent Pipeline Updates 74
Oligodendroglioma - Dormant Projects 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94

List of Tables

Number of Products under Development for Oligodendroglioma, H1 2015 9
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Oligodendroglioma - Pipeline by Cavion LLC, H1 2015 17
Oligodendroglioma - Pipeline by Celgene Corporation, H1 2015 18
Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H1 2015 19
Oligodendroglioma - Pipeline by e-Therapeutics plc, H1 2015 20
Oligodendroglioma - Pipeline by Eli Lilly and Company, H1 2015 21
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 22
Oligodendroglioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 23
Oligodendroglioma - Pipeline by Novartis AG, H1 2015 24
Oligodendroglioma - Pipeline by Orbus Therapeutics, Inc., H1 2015 25
Oligodendroglioma - Pipeline by Sanofi, H1 2015 26
Oligodendroglioma - Pipeline by Tocagen Inc., H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Assessment by Combination Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Oligodendroglioma Therapeutics - Recent Pipeline Updates, H1 2015 74
Oligodendroglioma - Dormant Projects, H1 2015 92